무세포 RNA 분석 시장 규모, 점유율 및 동향 분석 보고서 : 제품·서비스별, 기술별, 용도별, 최종 용도별, 지역별 및 부문별 예측(2026-2033년)

Cell-Free RNA Analysis Market Summary

The global cell-free RNA analysis market size was valued at USD 43.3 million in 2025 and is projected to grow from USD 49.5 million in 2026 to USD 131.6 million by 2033, at a CAGR of 15.0% from 2026 to 2033. North America dominated the market, accounting for the largest revenue share of 39.2% in 2025. The industry is driven by increasing adoption of cfRNA analysis for liquid biopsy, biomarker discovery, precision medicine, disease monitoring, and molecular diagnostics, along with advancements in sequencing and RNA analysis technologies.

Global Cell-free RNA Analysis Market Report Segmentation

This report forecasts revenue growth at the global, regional and country levels and provides an analysis on the latest trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global cell-free RNA analysis market report on the basis of product & service, technology, application, end-use, and region:

• Product & Service Outlook (Revenue, USD Million, 2021 - 2033)
• Reagents & Kits
• Instruments & Systems
• Consumables
• Analysis & Testing Services
• Technology Outlook (Revenue, USD Million, 2021 - 2033)
• RNA Sequencing (RNA-seq/NGS)
• Digital PCR (dPCR)
• RT-qPCR / qPCR
• Microarray Analysis
• Other Technologies
• Application Outlook (Revenue, USD Million, 2021 - 2033)
• Oncology
• Prenatal Screening & Maternal Health
• Transplant Monitoring
• Infectious Disease
• Neurological Disorders
• Cardiovascular & Metabolic Disorders
• Research & Drug Development
• Other Applications
• End-use Outlook (Revenue, USD Million, 2021 - 2033)
• Pharmaceutical & Biotechnology Companies
• Hospitals & Clinics
• Diagnostic Laboratories
• Academic & Research Institutes
• Regional Outlook (Revenue, USD Million, 2021 - 2033)
• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • UK
  • Germany
  • France
  • Italy
  • Spain
  • Denmark
  • Sweden
  • Norway
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • Thailand
  • South Korea
• Latin America
  • Brazil
  • Argentina
• Middle East and Africa (MEA)
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation and Scope
  • 1.1.1. Segment Definitions
    • 1.1.1.1. Product & Service Segment
    • 1.1.1.2. Technology Segment
    • 1.1.1.3. Application Segment
    • 1.1.1.4. End User Segment
• 1.2. Regional Scope
• 1.3. Estimates and Forecast Timeline
• 1.4. Objectives
• 1.5. Research Methodology
• 1.6. Information Procurement
  • 1.6.1. Purchased Database
  • 1.6.2. GVR's Internal Database
  • 1.6.3. Secondary Sources
  • 1.6.4. Primary Research
• 1.7. Information or Data Analysis:
  • 1.7.1. Data Analysis Models
• 1.8. Market Formulation & Validation
• 1.9. Model Details
  • 1.9.1. Commodity Flow Analysis
  • 1.9.2. List of Secondary Sources
  • 1.9.3. List of Abbreviations

Chapter 2. Executive Summary

• 2.1. Market Snapshot
• 2.2. Segment Snapshot
• 2.3. Competitive Landscape Snapshot

Chapter 3. Market Variables, Trends, & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent Market Outlook
  • 3.1.2. Related/Ancillary Market Outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
    • 3.2.1.1. Growing adoption of liquid biopsy for minimally invasive disease detection and monitoring
    • 3.2.1.2. Rising cancer burden and demand for early cancer detection
    • 3.2.1.3. Advancements in NGS, PCR, and multi-omics technologies
  • 3.2.2. Market Restraint Analysis
    • 3.2.2.1. Limited clinical validation of cfRNA biomarkers
    • 3.2.2.2. High variability and instability of cfRNA in biological samples
  • 3.2.3. Market Opportunities Analysis
  • 3.2.4. Market Challenges Analysis
• 3.3. Industry Analysis Tools
  • 3.3.1. Porter's Five Forces Analysis
    • 3.3.1.1. Supplier power
    • 3.3.1.2. Buyer power
    • 3.3.1.3. Substitution threat
    • 3.3.1.4. Threat of new entrant
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTLE Analysis
    • 3.3.2.1. Political landscape
    • 3.3.2.2. Technological landscape
    • 3.3.2.3. Social landscape
    • 3.3.2.4. Economic landscape
    • 3.3.2.5. Legal landscape

Chapter 4. Product & Service Business Analysis

• 4.1. Segment Dashboard
• 4.2. Cell-Free RNA Analysis Market: Product & Service Movement Analysis
• 4.3. Reagents & Kits
  • 4.3.1. Reagents & Kits Market, 2021 - 2033 (USD Million)
• 4.4. Instruments & Systems
  • 4.4.1. Instruments & Systems Market, 2021 - 2033 (USD Million)
• 4.5. Consumables
  • 4.5.1. Consumables Market, 2021 - 2033 (USD Million)
• 4.6. Analysis & Testing Services
  • 4.6.1. Analysis & Testing Services Market, 2021 - 2033 (USD Million)

Chapter 5. Technology Business Analysis

• 5.1. Segment Dashboard
• 5.2. Cell-Free RNA Analysis Market: Technology Movement Analysis
• 5.3. RNA Sequencing (RNA-seq/NGS)
  • 5.3.1. RNA Sequencing (RNA-seq/NGS) Market, 2021 - 2033 (USD Million)
• 5.4. Digital PCR (dPCR)
  • 5.4.1. Digital PCR (dPCR) Market, 2021 - 2033 (USD Million)
• 5.5. RT-qPCR / qPCR
  • 5.5.1. RT-qPCR / qPCR Market, 2021 - 2033 (USD Million)
• 5.6. Microarray Analysis
  • 5.6.1. Microarray Analysis Market, 2021 - 2033 (USD Million)
• 5.7. Other Technologies
  • 5.7.1. Other Technologies Market, 2021 - 2033 (USD Million)

Chapter 6. Application Business Analysis

• 6.1. Segment Dashboard
• 6.2. Cell-Free RNA Analysis Market: Application Movement Analysis
• 6.3. Oncology
  • 6.3.1. Oncology Market, 2021 - 2033 (USD Million)
• 6.4. Prenatal Screening & Maternal Health
  • 6.4.1. Prenatal Screening & Maternal Health Market, 2021 - 2033 (USD Million)
• 6.5. Transplant Monitoring
  • 6.5.1. Transplant Monitoring Market, 2021 - 2033 (USD Million)
• 6.6. Infectious Disease
  • 6.6.1. Infectious Disease Market, 2021 - 2033 (USD Million)
• 6.7. Neurological Disorders
  • 6.7.1. Neurological Disorders Market, 2021 - 2033 (USD Million)
• 6.8. Cardiovascular & Metabolic Disorders
  • 6.8.1. Cardiovascular & Metabolic Disorders Market, 2021 - 2033 (USD Million)
• 6.9. Research & Drug Development
  • 6.9.1. Research & Drug Development Market, 2021 - 2033 (USD Million)
• 6.10. Other Applications
  • 6.10.1. Other Applications Market, 2021 - 2033 (USD Million)

Chapter 7. End Use Business Analysis

• 7.1. Segment Dashboard
• 7.2. Cell-Free RNA Analysis Market: End Use Movement Analysis
• 7.3. Pharmaceutical & Biotechnology Companies
  • 7.3.1. Pharmaceutical & Biotechnology Companies Market, 2021 - 2033 (USD Million)
• 7.4. Hospitals & Clinics
  • 7.4.1. Hospitals & Clinics Market, 2021 - 2033 (USD Million)
• 7.5. Diagnostic Laboratories
  • 7.5.1. Diagnostic Laboratories Market, 2021 - 2033 (USD Million)
• 7.6. Academic & Research Institutes
  • 7.6.1. Academic & Research Institutes Market, 2021 - 2033 (USD Million)

Chapter 8. Regional Business Analysis

• 8.1. Cell-Free RNA Analysis Market Share By Region, 2025 & 2033
• 8.2. North America
  • 8.2.1. North America Cell-Free RNA Analysis Market, 2021 - 2033 (USD Million)
  • 8.2.2. U.S.
    • 8.2.2.1. Key Country Dynamics
    • 8.2.2.2. Competitive Scenario
    • 8.2.2.3. Regulatory Framework
    • 8.2.2.4. U.S. Cell-Free RNA Analysis Market, 2021 - 2033 (USD Million)
  • 8.2.3. Canada
    • 8.2.3.1. Key Country Dynamics
    • 8.2.3.2. Competitive Scenario
    • 8.2.3.3. Regulatory Framework
    • 8.2.3.4. Canada Cell-Free RNA Analysis Market, 2021 - 2033 (USD Million)
  • 8.2.4. Mexico
    • 8.2.4.1. Key Country Dynamics
    • 8.2.4.2. Competitive Scenario
    • 8.2.4.3. Regulatory Framework
    • 8.2.4.4. Mexico Cell-Free RNA Analysis Market, 2021 - 2033 (USD Million)
• 8.3. Europe
  • 8.3.1. Europe Cell-Free RNA Analysis Market, 2021 - 2033 (USD Million)
  • 8.3.2. UK
    • 8.3.2.1. Key Country Dynamics
    • 8.3.2.2. Competitive Scenario
    • 8.3.2.3. Regulatory Framework
    • 8.3.2.4. UK Cell-Free RNA Analysis Market, 2021 - 2033 (USD Million)
  • 8.3.3. Germany
    • 8.3.3.1. Key Country Dynamics
    • 8.3.3.2. Competitive Scenario
    • 8.3.3.3. Regulatory Framework
    • 8.3.3.4. Germany Cell-Free RNA Analysis Market, 2021 - 2033 (USD Million)
  • 8.3.4. France
    • 8.3.4.1. Key Country Dynamics
    • 8.3.4.2. Competitive Scenario
    • 8.3.4.3. Regulatory Framework
    • 8.3.4.4. France Cell-Free RNA Analysis Market, 2021 - 2033 (USD Million)
  • 8.3.5. Italy
    • 8.3.5.1. Key Country Dynamics
    • 8.3.5.2. Competitive Scenario
    • 8.3.5.3. Regulatory Framework
    • 8.3.5.4. Italy Cell-Free RNA Analysis Market, 2021 - 2033 (USD Million)
  • 8.3.6. Spain
    • 8.3.6.1. Key Country Dynamics
    • 8.3.6.2. Competitive Scenario
    • 8.3.6.3. Regulatory Framework
    • 8.3.6.4. Spain Cell-Free RNA Analysis Market, 2021 - 2033 (USD Million)
  • 8.3.7. Denmark
    • 8.3.7.1. Key Country Dynamics
    • 8.3.7.2. Competitive Scenario
    • 8.3.7.3. Regulatory Framework
    • 8.3.7.4. Denmark Cell-Free RNA Analysis Market, 2021 - 2033 (USD Million)
  • 8.3.8. Sweden
    • 8.3.8.1. Key Country Dynamics
    • 8.3.8.2. Competitive Scenario
    • 8.3.8.3. Regulatory Framework
    • 8.3.8.4. Sweden Cell-Free RNA Analysis Market, 2021 - 2033 (USD Million)
  • 8.3.9. Norway
    • 8.3.9.1. Key Country Dynamics
    • 8.3.9.2. Competitive Scenario
    • 8.3.9.3. Regulatory Framework
    • 8.3.9.4. Norway Cell-Free RNA Analysis Market, 2021 - 2033 (USD Million)
• 8.4. Asia Pacific
  • 8.4.1. Asia Pacific Cell-Free RNA Analysis Market, 2021 - 2033 (USD Million)
  • 8.4.2. Japan
    • 8.4.2.1. Key Country Dynamics
    • 8.4.2.2. Competitive Scenario
    • 8.4.2.3. Regulatory Framework
    • 8.4.2.4. Japan Cell-Free RNA Analysis Market, 2021 - 2033 (USD Million)
  • 8.4.3. China
    • 8.4.3.1. Key Country Dynamics
    • 8.4.3.2. Competitive Scenario
    • 8.4.3.3. Regulatory Framework
    • 8.4.3.4. China Cell-Free RNA Analysis Market, 2021 - 2033 (USD Million)
  • 8.4.4. India
    • 8.4.4.1. Key Country Dynamics
    • 8.4.4.2. Competitive Scenario
    • 8.4.4.3. Regulatory Framework
    • 8.4.4.4. India Cell-Free RNA Analysis Market, 2021 - 2033 (USD Million)
  • 8.4.5. Australia
    • 8.4.5.1. Key Country Dynamics
    • 8.4.5.2. Competitive Scenario
    • 8.4.5.3. Regulatory Framework
    • 8.4.5.4. Australia Cell-Free RNA Analysis Market, 2021 - 2033 (USD Million)
  • 8.4.6. Thailand
    • 8.4.6.1. Key Country Dynamics
    • 8.4.6.2. Competitive Scenario
    • 8.4.6.3. Regulatory Framework
    • 8.4.6.4. Thailand Cell-Free RNA Analysis Market, 2021 - 2033 (USD Million)
  • 8.4.7. South Korea
    • 8.4.7.1. Key Country Dynamics
    • 8.4.7.2. Competitive Scenario
    • 8.4.7.3. Regulatory Framework
    • 8.4.7.4. South Korea Cell-Free RNA Analysis Market, 2021 - 2033 (USD Million)
• 8.5. Latin America
  • 8.5.1. Latin America Cell-Free RNA Analysis Market, 2021 - 2033 (USD Million)
  • 8.5.2. Brazil
    • 8.5.2.1. Key Country Dynamics
    • 8.5.2.2. Competitive Scenario
    • 8.5.2.3. Regulatory Framework
    • 8.5.2.4. Brazil Cell-Free RNA Analysis Market, 2021 - 2033 (USD Million)
  • 8.5.3. Argentina
    • 8.5.3.1. Key Country Dynamics
    • 8.5.3.2. Competitive Scenario
    • 8.5.3.3. Regulatory Framework
    • 8.5.3.4. Argentina Cell-Free RNA Analysis Market, 2021 - 2033 (USD Million)
• 8.6. MEA
  • 8.6.1. MEA Cell-Free RNA Analysis Market, 2021 - 2033 (USD Million)
  • 8.6.2. South Africa
    • 8.6.2.1. Key Country Dynamics
    • 8.6.2.2. Competitive Scenario
    • 8.6.2.3. Regulatory Framework
    • 8.6.2.4. South Africa Cell-Free RNA Analysis Market, 2021 - 2033 (USD Million)
  • 8.6.3. Saudi Arabia
    • 8.6.3.1. Key Country Dynamics
    • 8.6.3.2. Competitive Scenario
    • 8.6.3.3. Regulatory Framework
    • 8.6.3.4. Saudi Arabia Cell-Free RNA Analysis Market, 2021 - 2033 (USD Million)
  • 8.6.4. UAE
    • 8.6.4.1. Key Country Dynamics
    • 8.6.4.2. Competitive Scenario
    • 8.6.4.3. Regulatory Framework
    • 8.6.4.4. UAE Cell-Free RNA Analysis Market, 2021 - 2033 (USD Million)
  • 8.6.5. Kuwait
    • 8.6.5.1. Key Country Dynamics
    • 8.6.5.2. Competitive Scenario
    • 8.6.5.3. Regulatory Framework
    • 8.6.5.4. Kuwait Cell-Free RNA Analysis Market, 2021 - 2033 (USD Million)

Chapter 9. Competitive Landscape

• 9.1. Company Categorization
• 9.2. Company Market Share/ Position Analysis, 2025
• 9.3. Strategy Mapping
• 9.4. Company Profiles/Listing
  • 9.4.1. QIAGEN
    • 9.4.1.1. Overview
    • 9.4.1.2. Financial Performance
    • 9.4.1.3. Product Benchmarking
    • 9.4.1.4. Strategic Initiatives
  • 9.4.2. Thermo Fisher Scientific Inc.
    • 9.4.2.1. Overview
    • 9.4.2.2. Financial Performance
    • 9.4.2.3. Product Benchmarking
    • 9.4.2.4. Strategic Initiatives
  • 9.4.3. Norgen Biotek Corp.
    • 9.4.3.1. Overview
    • 9.4.3.2. Financial Performance
    • 9.4.3.3. Product Benchmarking
    • 9.4.3.4. Strategic Initiatives
  • 9.4.4. Zymo Research Corporation
    • 9.4.4.1. Overview
    • 9.4.4.2. Financial Performance
    • 9.4.4.3. Product Benchmarking
    • 9.4.4.4. Strategic Initiatives
  • 9.4.5. New England Biolabs
    • 9.4.5.1. Overview
    • 9.4.5.2. Financial Performance
    • 9.4.5.3. Product Benchmarking
    • 9.4.5.4. Strategic Initiatives
  • 9.4.6. Illumina, Inc.
    • 9.4.6.1. Overview
    • 9.4.6.2. Financial Performance
    • 9.4.6.3. Product Benchmarking
    • 9.4.6.4. Strategic Initiatives
  • 9.4.7. Revvity
    • 9.4.7.1. Overview
    • 9.4.7.2. Financial Performance
    • 9.4.7.3. Product Benchmarking
    • 9.4.7.4. Strategic Initiatives
  • 9.4.8. Beckman Coulter Life Sciences
    • 9.4.8.1. Overview
    • 9.4.8.2. Financial Performance
    • 9.4.8.3. Product Benchmarking
    • 9.4.8.4. Strategic Initiatives
  • 9.4.9. PlexBio Co., Ltd.
    • 9.4.9.1. Overview
    • 9.4.9.2. Financial Performance
    • 9.4.9.3. Product Benchmarking
    • 9.4.9.4. Strategic Initiatives
  • 9.4.10. Geneaid Biotech Ltd.
    • 9.4.10.1. Overview
    • 9.4.10.2. Financial Performance
    • 9.4.10.3. Product Benchmarking
    • 9.4.10.4. Strategic Initiatives
  • 9.4.11. Bio-Rad Laboratories, Inc.
    • 9.4.11.1. Overview
    • 9.4.11.2. Financial Performance
    • 9.4.11.3. Product Benchmarking
    • 9.4.11.4. Strategic Initiatives
  • 9.4.12. nRichDX
    • 9.4.12.1. Overview
    • 9.4.12.2. Financial Performance
    • 9.4.12.3. Product Benchmarking
    • 9.4.12.4. Strategic Initiatives